FOLH1 and metastatic neoplasm: We found that PSMA‐PET/CT effectively differentiates between regional and distant metastatic disease at a median PSA level of 0.39 ng/ml, above the threshold typically considered for early salvage (radio)therapy (i.e., 0.25 ng/ml).29